257 related articles for article (PubMed ID: 7907797)
1. Activity of the new histamine H2-receptor antagonist zolantidine at cardiac and gastric H2-receptors.
Coruzzi G; Adami M; Pozzoli C; Poli E; Bertaccini G
Pharmacology; 1994 Feb; 48(2):69-76. PubMed ID: 7907797
[TBL] [Abstract][Full Text] [Related]
2. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
Cavanagh RL; Usakewicz JJ; Buyniski JP
J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
[TBL] [Abstract][Full Text] [Related]
3. Effects of histamine H2 receptor agonists and antagonists on the isolated guinea pig gallbladder.
Coruzzi G; Pozzoli C; Poli E; Coppelli G; Bertaccini G
Fundam Clin Pharmacol; 1999; 13(1):84-90. PubMed ID: 10027092
[TBL] [Abstract][Full Text] [Related]
4. Different effects of the histamine H2 receptor blockers, famotidine and zolantidine, on the human atrium in vitro.
Poli E; Pozzoli C; Barboso G; Bertaccini G
Arch Int Pharmacodyn Ther; 1994; 328(2):180-90. PubMed ID: 7710303
[TBL] [Abstract][Full Text] [Related]
5. Cardiac and gastric effects of histamine H2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity.
Coruzzi G; Adami M; Pozzoli C; Giorgi F; Bertaccini G
Br J Pharmacol; 1996 Aug; 118(7):1813-21. PubMed ID: 8842448
[TBL] [Abstract][Full Text] [Related]
6. Zolantidine (SK&F 95282) is a potent selective brain-penetrating histamine H2-receptor antagonist.
Calcutt CR; Ganellin CR; Griffiths R; Leigh BK; Maguire JP; Mitchell RC; Mylek ME; Parsons ME; Smith IR; Young RC
Br J Pharmacol; 1988 Jan; 93(1):69-78. PubMed ID: 2894879
[TBL] [Abstract][Full Text] [Related]
7. Antisecretory and antiulcer activities of a potent new histamine H2-receptor antagonist with an intermediate duration of action.
Borella L; Russell J; Rimele TJ; Grimes D; Failli A; Mir GN
Arzneimittelforschung; 1988 Mar; 38(3):366-72. PubMed ID: 2898247
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro effects of CM 57755, a new gastric antisecretory agent acting on histamine H2 receptors.
Lavezzo A; Manzoni L; Aureggi G; Nisato D; Bianchetti A; Carminati P
Int J Tissue React; 1984; 6(2):155-65. PubMed ID: 6145676
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of mifentidine, a novel H2-receptor antagonist.
Pagani F; Micheletti R; Brambilla A; Schiavone A; Montagna E; Ciprandi C; Giachetti A
Arzneimittelforschung; 1985; 35(1A):451-5. PubMed ID: 2859036
[TBL] [Abstract][Full Text] [Related]
10. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
11. In vitro cardiac pharmacology of the new histamine H2-receptor agonist amthamine: comparisons with histamine and dimaprit.
Poli E; Pozzoli C; Coruzzi G; Bertaccini G; Timmerman H
Agents Actions; 1993 Sep; 40(1-2):44-9. PubMed ID: 8147269
[TBL] [Abstract][Full Text] [Related]
12. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine.
Daly MJ; Humphray JM; Stables R
Br J Pharmacol; 1981 Jan; 72(1):49-54. PubMed ID: 6112034
[TBL] [Abstract][Full Text] [Related]
13. FR145715, a novel histamine H2 receptor antagonist, with specific anti-Helicobacter pylori activities.
Ishikawa H; Ito H; Higaki M; Higaki M; Matsumoto Y; Kamimura T; Katsura Y; Tomishi T; Inoue Y; Takasugi H; Tomoi M; Krakowka S; Yoshida K
Eur J Pharmacol; 1999 Aug; 378(3):299-310. PubMed ID: 10493106
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of ORF 17578, a new histamine H2-receptor antagonist: comparison with cimetidine and ranitidine.
Katz LB; Scott CK; Shriver DA
J Pharmacol Exp Ther; 1986 May; 237(2):404-10. PubMed ID: 2871172
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of JB-9315, a new selective histamine H2-receptor antagonist.
Palacios B; Montero MJ; Sevilla MA; San Román L
Gen Pharmacol; 1998 Feb; 30(2):181-9. PubMed ID: 9502172
[TBL] [Abstract][Full Text] [Related]
16. Studies on MK-208 (YM-11170) a new, slowly dissociable H2-receptor antagonist.
Pendleton RG; Torchiana ML; Chung C; Cook P; Wiese S; Clineschmidt BV
Arch Int Pharmacodyn Ther; 1983 Nov; 266(1):4-16. PubMed ID: 6141772
[TBL] [Abstract][Full Text] [Related]
17. [Effect of a new H2 receptor antagonist, famotidine, on gastric secretion].
Noci MT; Coruzzi G
Boll Soc Ital Biol Sper; 1986 Sep; 62(9):1103-9. PubMed ID: 2879549
[No Abstract] [Full Text] [Related]
18. Action of the new H2-antagonist, DA 4577, on different in vitro and in vivo preparations.
Bertaccini G; Poli E; Coruzzi G
Agents Actions; 1984 Apr; 14(3-4):510-5. PubMed ID: 6145337
[TBL] [Abstract][Full Text] [Related]
19. The antisecretory profile of action of the H2-receptor antagonists, famotidine, loxtidine, ranitidine and L-643,441 on the rat isolated gastric mucosa.
Reeves JJ; Stables R
Agents Actions; 1987 Feb; 20(1-2):22-8. PubMed ID: 2883848
[TBL] [Abstract][Full Text] [Related]
20. Histamine H2-receptor blocking activity of ranitidine and lamtidine analogues containing aminomethyl-substituted aliphatic systems.
Orsetti M
Agents Actions; 1988 Dec; 25(3-4):291-5. PubMed ID: 2905866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
